TY - JOUR
T1 - Effect of baseline characteristics on the efficacy and safety of once-daily darunavir/ ritonavir in HIV-1-infected, treatment-naïve ARTEMIS patients at week 96
AU - Fourie, Jan
AU - Flamm, Jason
AU - Rodriguez-French, Amalia
AU - Kilby, Don
AU - Domingo, Pere
AU - Lazzarin, Adriano
AU - Ballesteros, Juan
AU - Sosa, Nestor
AU - Van De Casteele, Tom
AU - Demasi, Ralph
AU - Spinosa-Guzman, Sabrina
AU - Lavreys, Ludo
PY - 2011/1/1
Y1 - 2011/1/1
N2 - Objectives: ARTEMIS demonstrated significantly greater efficacy of once-daily darunavir/ritonavir (DRV/r) 800/100 mg versus lopinavir/ritonavir 800/200 mg (total daily dose) in treatment-naïve, HIV-1-infected patients at week 96. The influence of baseline characteristics on efficacy and safety was analyzed in DRV/r patients. Methods: Patients received once-daily DRV/r plus fixed-dose tenofovir/emtric-itabine. Week 96 efficacy and safety data were analyzed by gender (males, n = 239; females, n = 104), age (≤30, n = 115; 31-45, n = 175; >45, n = 53), race (Asian, n = 44; Black, n = 80; Caucasian/White, n = 137; Hispanic, n = 77), and hepatitis B and/or C virus coinfection (n = 43). Results: Week 96 virologic response rates (HIV-1 RNA 45); race: 96% (Asian), 71% (Black), 77% (Caucasian/White), and 79% (Hispanic); coinfection status: 72% (coinfected) and 80% (non-coinfected). The incidence of treatment-related adverse drug reactions (ADRs) and laboratory abnormalities were comparable across gender, age, and race subgroups. Coinfected patients had a higher incidence of liver-related ADRs than non-coinfected patients. Conclusions: DRV/r 800/100 mg qd is an effective, well-tolerated treatment option for treatment-naïve patients of different gender, age, race, or coinfection status.
AB - Objectives: ARTEMIS demonstrated significantly greater efficacy of once-daily darunavir/ritonavir (DRV/r) 800/100 mg versus lopinavir/ritonavir 800/200 mg (total daily dose) in treatment-naïve, HIV-1-infected patients at week 96. The influence of baseline characteristics on efficacy and safety was analyzed in DRV/r patients. Methods: Patients received once-daily DRV/r plus fixed-dose tenofovir/emtric-itabine. Week 96 efficacy and safety data were analyzed by gender (males, n = 239; females, n = 104), age (≤30, n = 115; 31-45, n = 175; >45, n = 53), race (Asian, n = 44; Black, n = 80; Caucasian/White, n = 137; Hispanic, n = 77), and hepatitis B and/or C virus coinfection (n = 43). Results: Week 96 virologic response rates (HIV-1 RNA 45); race: 96% (Asian), 71% (Black), 77% (Caucasian/White), and 79% (Hispanic); coinfection status: 72% (coinfected) and 80% (non-coinfected). The incidence of treatment-related adverse drug reactions (ADRs) and laboratory abnormalities were comparable across gender, age, and race subgroups. Coinfected patients had a higher incidence of liver-related ADRs than non-coinfected patients. Conclusions: DRV/r 800/100 mg qd is an effective, well-tolerated treatment option for treatment-naïve patients of different gender, age, race, or coinfection status.
KW - darunavir
KW - efficacy
KW - HIV
KW - safety
KW - treatment-naïve
UR - http://www.scopus.com/inward/record.url?scp=84255200717&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84255200717&partnerID=8YFLogxK
U2 - 10.1310/hct1206-313
DO - 10.1310/hct1206-313
M3 - Article
C2 - 22189150
AN - SCOPUS:84255200717
VL - 12
SP - 313
EP - 322
JO - HIV Clinical Trials
JF - HIV Clinical Trials
SN - 1528-4336
IS - 6
ER -